Evidence map›Paper›PMID 31504345›Full record

ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections.

Juliana S Grant, Chrysovalantis Stafylis, Connie Celum, Troy Grennan, Bridget Haire, John Kaldor, Anne F Luetkemeyer, John M Saunders, Jean-Michel Molina, Jeffrey D Klausner

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 4 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2024
    Guideline
  4. Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021
    Guideline
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 5 countries.

Juliana S GrantJSG Health, LLC, Seattle, Washington DC, USA.
Chrysovalantis StafylisDivision of Infectious Diseases, University of California-Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, California, USA.
Connie CelumDepartment of Global Health, University of Washington, Seattle, Washington DC, USA.
Troy GrennanBritish Columbia Centre for Disease Control and Division of Infectious Diseases, University of British Columbia, Vancouver, Canada.
Bridget HaireThe Kirby Institute, University of New South Wales, Sydney, Australia.
John KaldorThe Kirby Institute, University of New South Wales, Sydney, Australia.
Anne F LuetkemeyerZuckerberg San Francisco General, University of California, San Francisco, California, USA.
John M SaundersBlood Safety, Hepatitis, STI, and HIV Division, National Infection Service, Public Health England, London, United Kingdom.
Jean-Michel MolinaDepartment of Infectious Diseases, St-Louis Hospital, University of Paris Diderot, Paris, France.
Jeffrey D KlausnerDivision of Infectious Diseases, University of California-Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, California, USA.
University of California, Los Angeles · USUNSW Sydney · AUBC Centre for Disease Control · CAPublic Health England · GBUniversité Paris Cité · FRUniversity of California, San Francisco · USUniversity of Washington · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9M
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with menR01AI143439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CELUM, CONNIE L, LUETKEMEYER, ANNE FREY · 2019 to 2023
$8.3M
Syphilis Immunology and Biology to Improve Clinical Management and Vaccine DesignR01AI139265 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Jeffrey David Klausner · 2018 to 2026
$4.8M
NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI139265NIAID NIH HHS R01 AI143439
6 · The paper itself

Abstract

Bacterial sexually transmitted infections (STIs) have been increasing over the past 2 decades in gay, bisexual, and other men who have sex with men. With the widespread use of early human immunodeficiency virus (HIV) treatment, which virtually eliminates transmission risk, and the availability of HIV pre-exposure prophylaxis, there have been attitudinal changes regarding HIV infection with resultant increases in sexual contact and declines in condom use. Doxycycline is used for primary prophylaxis in a number of infectious diseases. We conducted a state-of-the-art review to examine the current state of research, knowledge gaps, and challenges around the use of doxycycline prophylaxis to prevent syphilis and other STIs. International academic and government experts met in March 2019 to frame the initial inquiry, which was supplemented by focused literature searches. Two small short-term randomized controlled trials examining doxycycline prophylaxis found high efficacy. Five additional clinical studies are underway or in development. Studies differed in design, population, outcomes, and safety measures. Doxycycline prophylaxis for bacterial STIs shows promise. Better and more robust data are needed on efficacy; target population; community acceptability; behavioral risk compensation; doxycycline dose, regimen, and formulation; long-term safety; antimicrobial resistance; cost-effectiveness; and risk-benefit.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesSexually Transmitted DiseasesDoxycyclineHomosexuality, MaleHumansMaleDoxycyclinechlamydiadoxycyclinemen who have sex with menprophylaxissyphilis

Identifiers

PMID31504345
PMCPMC7319058
OpenAlexW2970886640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.